Maria Fife
Family · Stayton, ORNPI 1801211560
Payments from drug & device makers
Across 38 payments — averaging $17.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$208
- Novo Nordisk$71
- Lilly USA, LLC$53
- Pfizer$51
- Takeda Pharmaceuticals U.S.A., Inc.$51
- AstraZeneca$34
- plus $192 from 9 others
What the payments were for
- Food & beverage$64498%
- Education$162%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 14 | $208 |
| Novo Nordisk | 3 | $71 |
| Lilly USA, LLC | 3 | $53 |
| Pfizer | 2 | $51 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $51 |
| AstraZeneca | 2 | $34 |
| Biohaven Pharmaceuticals, Inc. | 2 | $32 |
| Sanofi-aventis U.S. LLC | 2 | $32 |
| Boehringer Ingelheim | 1 | $26 |
| Bayer | 1 | $20 |
| Organon | 1 | $19 |
| GSK | 1 | $19 |
| Coopersurgical, Inc. | 1 | $18 |
| Indivior Inc. | 1 | $15 |
| Exact Sciences | 1 | $13 |
How this compares
$660 in reported general payments places this provider in the 75th percentile of 1,130 family providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 106 | $85,471 |
| TrulicityDulaglutide | 48 | $52,289 |
| OzempicSemaglutide | 32 | $48,479 |
| MounjaroTirzepatide | 33 | $33,822 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 43 | $31,638 |
| EliquisApixaban | 25 | $27,011 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 13 | $14,749 |
| Breo ElliptaFluticasone/Vilanterol | 22 | $14,660 |
| TradjentaLinagliptin | 19 | $14,031 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $13,399 |
| LinzessLinaclotide | 22 | $11,454 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $10,300 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 18 | $9,224 |
| TrintellixVortioxetine Hydrobromide | 20 | $8,750 |
| Spiriva RespimatTiotropium Bromide | 16 | $8,223 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat, Spiriva Respimat | $26 | $116,949159 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $53 | $86,11181 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $19 | $56,59876 claims |
| Novo NordiskOzempic | $71 | $48,47932 claims |
| PfizerEliquis | $51 | $27,01125 claims |
| AbbVieLinzess, Synthroid | $208 | $12,64544 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $51 | $8,75020 claims |
| AstraZenecaFarxiga | $34 | $7,34511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,130 family providers in Oregon.
Other family in Stayton
- Rachel PangilinanPortland$103K
- Jodeanna SweeneyCentral Point$45K
- Lani DoserPortland$45K
- David ArnopoleMedford$38K
- Heather HermanCorvallis$34K
- Amy BartramOregon City$33K
- Leah GaedekePortland$26K
- Bobbi Lee RothTualatin$23K
- Susan ToftePortland$21K
- Leah WessenbergPortland$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.